Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

ter the first cycle of atacicept. Accrual and treatment of one additional cohort of B-CLL patients at a higher dose level is ongoing.

Abstract

The abstract is available at http://www.zymogenetics.com in the "What's New" section on the home page.

About Atacicept

ZymoGenetics and Merck Serono, an affiliate of Merck KGaA, Darmstadt, Germany, are developing atacicept (formerly referred to as TACI-Ig) for the treatment of autoimmune diseases and B-cell malignancies. Atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as systemic lupus erythematosus (SLE). Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, SLE and B-cell malignancies. Atacicept has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies.

About ZymoGenetics

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit http://www.zymogenetics.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... - Finding May Refine Drug Targets for Personalized Treatments ... new genes that increase the risk of developing inflammatory,bowel ... needed to identify the specific disease-causing,mutations in these new ... to be added to the list of genes already,known ...
... centers to collaborate on studies of immunosuppression ... immunity, COLUMBIA, Md., Aug. 28 "Cylex, Inc., ... delighted to be able to,announce our support for a ... at seven highly respected medical institutions,in the Republic of ...
Cached Medicine Technology:New Genes Found for Inflammatory Bowel Disease in Children 2New Genes Found for Inflammatory Bowel Disease in Children 3New Genes Found for Inflammatory Bowel Disease in Children 4Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 2Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 3
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, ... looking for an affordable gown can visit Discount-Dress.com ... get their dream items. Recently, the company has announced its ... Along with that, it is also providing great discounts for ... the deadline of this promotion is July 29, 2014. ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- Reducing the number of ... of Lyme disease and other tick-borne infections among people, ... populations can be manipulated to reduce human interactions with ... Lyme disease," the researchers wrote. White-tailed deer are ... Lyme disease to people. The study included nearly ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Microbiology testing ... the in-vitro diagnostics industry, which is expected to pose ... years. The sector owes its growth to the ongoing ... people’s health worldwide and a major factor leading to ... threat of bio-terrorism, and a broader availability of immunosuppressants, ...
(Date:7/11/2014)... Datalogic brings a new and innovative scanner to ... their new Gryphon GD4400 and GM4400 anti-microbial ... MRSA, which claimed 5,500 lives, becomes more preventable. ... the Gryphon GM4400-HC 2D readers can scan nearly all ... off of troublesome LCD monitors, smartphones, and other mobile ...
Breaking Medicine News(10 mins):Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3
... ESA Envisat images capture the oil that is spilling into the ... the coasts of Louisiana and Mississippi, USA, on 22 April. ... a dark grey whirl in the bottom right, while in the ... Delta is at top left, and the Delta National Wildlife Refuge ...
... , ... to Support Acute Healthcare Services and Infection Control , ... Santa Clara, Calif. (PRWEB) April 27, 2010 -- ... announced today that Broomfield Hospital, part of Mid Essex Hospital Services NHS Trust, will ...
... ... during NACDS Annual Meeting , ... Palm Beach, FL (Vocus) April 27, 2010 -- In his first remarks as the newly ... ( NACDS ), Larry J. Merlo, president of CVS/pharmacy, paid tribute to the pharmacy icons ...
... age of iPads and hybrid cars, young Americans are more ... baby boom generation: They are living at home longer, are ... new study points out that a 22-year-old of today might ... or great-grandfather than their own parents, although the reasons for ...
... ... hundred hospitals, the medical demands of the residents of New York City are vast. ... City’s most important suppliers of donor blood and critical medical equipment rely on USPack Courier’s ... , ...
... for men with advanced disease, studies found, , TUESDAY, ... week of a therapeutic prostate cancer vaccine by the ... against the disease and cancer in general, experts say. ... in men with advanced prostate cancer, and it does ...
Cached Medicine News:Health News:NHS Mid Essex Prescribes Wireless Network For New Hospital Wing 2Health News:New NACDS Chairman Larry Merlo Emphasizes Personal Commitment, Connection to Pharmacy 2Health News:New NACDS Chairman Larry Merlo Emphasizes Personal Commitment, Connection to Pharmacy 3Health News:Lower wages, lack of job opportunities means more Americans delaying 'adulthood' 2Health News:Lower wages, lack of job opportunities means more Americans delaying 'adulthood' 3Health News:Lower wages, lack of job opportunities means more Americans delaying 'adulthood' 4Health News:USPack Courier Brings Tracking Precision to Medical and Blood Shipments 2Health News:USPack Courier Brings Tracking Precision to Medical and Blood Shipments 3Health News:Prostate Cancer Vaccine May Get FDA Approval 2Health News:Prostate Cancer Vaccine May Get FDA Approval 3
... for vascular treatments, Smart VS is the most ... fast amortisation of the investment made. Like all ... with a polarised light viewing system for ensuing ... as well as the operators maximum comfort. I ...
... is an exceptional condensate of ... dimensions for ensuring a rational ... constantly evolving professional market. PhotoLight ... in different studios who require ...
... 2000 system is a pulsed DYE laser ... specific pathologies like Port Wine Stains (PWS), ... pathologies of the trunk and the face. ... all these pathologies, the DYE laser naturally ...
... Plus is a CO2 laser system ... W. Its functions in continuous and ... requiring extreme laser intervention delicacy. Excellent ... studios, it comes with a large ...
Medicine Products: